Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance Pazopanib in NSCLC (MAPPING)
NCT01208064Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Jul 2011
- Primary completion
- Jun 2015
- Countries
- 8
01
Overview
A Phase 3 trial of pazopanib in non-small cell lung cancer (NSCLC), sponsored by European Organisation for Research and Treatment of Cancer. Started Jul 2011; status: terminated.
02
Drugs
pazopanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01208064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01208064.